Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genomics Laboratory, |
RCV001253801 | SCV001427206 | uncertain significance | PSAT deficiency; Neu-Laxova syndrome 2 | 2019-11-21 | no assertion criteria provided | clinical testing | The p.Arg319Lysfs*4 variant in the PSAT1 gene has not been previously reported in association with disease and was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant results in a 1 base pair insertion, which causes a shift in the protein reading frame, leading to a premature termination codon 4 amino acids downstream. This premature termination codon is within the last 50 base pairs of the of penultimate exon of PSAT1 and is not predicted to undergo nonsense-mediated decay. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Arg319Lysfs*4 variant is uncertain. Additional information is needed to resolve the significance of this variant. [ACMG evidence codes used: PM2; PM4] |